1 of Wall Street’s Top Picks to Watch Closely and 2 We Consider Risky

Wall Street Price Targets: Proceed with Caution

Analysts on Wall Street have set high price targets for the stocks discussed below, hinting at significant potential gains. However, it's wise to approach these projections with a healthy dose of skepticism, as industry pressures can sometimes result in forecasts that are more optimistic than realistic.

At StockStory, our only commitment is to help you identify truly promising investment opportunities, free from conflicts of interest. With that in mind, we highlight one stock where analyst enthusiasm seems justified, and two others where important risks may be underestimated.

Stocks to Consider Selling

UiPath (PATH)

Consensus Price Target: $15.93 (suggesting a 43.1% potential return)

UiPath (NYSE:PATH) began as a leader in robotic process automation and has since expanded into a robust automation platform powered by AI. Their technology allows businesses to deploy software robots that replicate human actions, streamlining repetitive workflows.

Reasons for Caution with PATH:

• Over the past two years, UiPath’s annual revenue growth averaged 13.2%, lagging behind the broader software sector.
• Billings increased by just 2.3% last year, indicating challenges in driving demand and possibly requiring price reductions to attract customers.
• Projected sales growth for the next year is 9.4%, pointing to a slowdown compared to recent trends.

Currently trading at $11.13 per share, UiPath’s forward price-to-sales ratio stands at 3.5.

Agilent (A)

Consensus Price Target: $161.72 (implying a 34.2% potential return)

Agilent Technologies (NYSE:A), originally part of Hewlett-Packard, specializes in analytical instruments, software, and services for laboratories in life sciences, diagnostics, and applied chemicals.

Why Agilent May Not Measure Up:

• Annual revenue growth of 2.4% over the last two years trails behind other healthcare companies.
• Recent organic sales trends suggest Agilent may need to pursue strategic changes or acquisitions to accelerate growth.
• Capital expenditures have increased over the past five years, with free cash flow margins dropping by 5.8 percentage points.

Agilent shares are priced at $120.53, reflecting a forward P/E of 19.7.

Stock Worth Watching

Accenture (ACN)

Consensus Price Target: $288.63 (projected 36.9% return)

Accenture (NYSE:ACN) is a global professional services leader, employing around 774,000 people and serving clients in over 120 countries. The company supports organizations in business transformation through consulting, technology, operations, and digital solutions.

What Sets ACN Apart?

• Accenture achieved impressive annual revenue growth of 9.6% over the past five years, indicating expanding market share.
• With a massive revenue base of $70.73 billion, the company enjoys considerable distribution advantages.
• Consistently strong returns on capital demonstrate management’s ability to invest in profitable opportunities.

Accenture’s current share price is $210.82, equating to a forward P/E of 15.1. Wondering if now is the right time to invest?

Top-Quality Stocks for Any Market

Bonus: The Top 5 Growth Stocks Right Now

Historically, the biggest stock market winners have shared one trait: explosive revenue growth. Companies like Meta, CrowdStrike, and Broadcom were all identified early by our AI, delivering returns of 315%, 314%, and 455%, respectively.

Curious about which five stocks our system is highlighting this month?

Past picks from 2020 include well-known names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Tecnoglass, which soared 1,754% over five years.